DCM
VKTX icon

DAFNA Capital Management’s Viking Therapeutics VKTX Stock Holding History

DAFNA Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.32M Hold
59,516
– – 0.44% 44
2026
Q1 		$1.94M Hold
59,516
– – 0.44% 47
2025
Q4 		$2.09M Sell
59,516
-5,000
-8% -$177K 0.49% 49
2025
Q3 		$1.7M Hold
64,516
– – 0.42% 49
2025
Q2 		$1.71M Hold
64,516
– – 0.47% 41
2025
Q1 		$1.56M Hold
64,516
– – 0.44% 43
2024
Q4 		$2.6M Sell
64,516
-61,100
-49% -$3.48M 0.66% 34
2024
Q3 		$7.95M Sell
125,616
-63,501
-34% -$3.73M 1.88% 20
2024
Q2 		$10M Sell
189,117
-5,000
-3% -$328K 2.4% 13
2024
Q1 		$15.9M Sell
194,117
-54,100
-22% -$2.41M 3.62% 7
2023
Q4 		$4.62M Sell
248,217
-71,438
-22% -$934K 1.11% 29
2023
Q3 		$3.54M Buy
319,655
+26,000
+9% +$372K 1.1% 29
2023
Q2 		$4.76M Sell
293,655
-25,500
-8% -$534K 1.3% 24
2023
Q1 		$5.31M Sell
319,155
-202,398
-39% -$2.09M 1.59% 19
2022
Q4 		$4.9M Sell
521,553
-30,847
-6% -$138K 1.38% 23
2022
Q3 		$1.5M Buy
552,400
+90,000
+19% +$295K 0.4% 47
2022
Q2 		$1.34M Buy
462,400
+15,000
+3% +$37.1K 0.36% 56
2022
Q1 		$1.34M Hold
447,400
– – 0.35% 65
2021
Q4 		$2.06M Hold
447,400
– – 0.52% 42
2021
Q3 		$2.81M Hold
447,400
– – 0.75% 34
2021
Q2 		$2.68M Hold
447,400
– – 0.56% 41
2021
Q1 		$2.83M Sell
447,400
-8,500
-2% -$59.8K 0.67% 38
2020
Q4 		$2.57M Buy
455,900
+5,000
+1% +$30.3K 0.76% 33
2020
Q3 		$2.62M Hold
450,900
– – 0.85% 32
2020
Q2 		$3.25M Hold
450,900
– – 0.94% 32
2020
Q1 		$2.11M Buy
450,900
+241,700
+116% +$1.49M 0.88% 32
2019
Q4 		$1.68M Hold
209,200
– – 0.58% 40
2019
Q3 		$1.44M Hold
209,200
– – 0.54% 49
2019
Q2 		$1.74M Buy
209,200
+30,000
+17% +$256K 0.65% 43
2019
Q1 		$1.78M Hold
179,200
– – 0.77% 42
2018
Q4 		$1.37M Buy
+179,200
New +$2.14M 0.68% 36

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

DAFNA Capital Management's VKTX Position: Q2 2026 in Review

DAFNA Capital Management held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 59,516 shares worth $2.32M. The position accounts for 0.44% of the portfolio, ranked #44.

DAFNA Capital Management first reported a position in VKTX in Q4 2018 and has held it in 31 quarters since. The position peaked at $15.9M in Q1 2024. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • DAFNA Capital Management held 59,516 shares of Viking Therapeutics worth $2.32M as of Q2 2026.
  • DAFNA Capital Management left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up 0.44% of DAFNA Capital Management's portfolio in Q2 2026, its #44 holding.
  • DAFNA Capital Management first reported a position in Viking Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • DAFNA Capital Management's Viking Therapeutics position peaked at $15.9M in Q1 2024.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on DAFNA Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.